#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Eosinophilic granulomatosis with polyangiitis Small cell lung cancer extensive stage Liposarcoma Pancreatic carcinoma Metastatic malignant melanoma Pemphigoid Multifocal motor neuropathy Pericarditis Infective uveitis Acute promyelocytic leukaemia Hodgkin's disease refractory Hodgkin's disease recurrent Medullary thyroid cancer Duchenne muscular dystrophy Chronic myeloid leukaemia More trials…

    Learn about Rare Diseases

    Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Diagnostics Niemann-Pick disease – Diagnostics VEXAS syndrome – Diagnostics Retinitis pigmentosa – Treatment Nephrotic syndrome – Trials in Disease Alternating hemiplegia of childhood – Basic Information Hereditary hypophosphataemic rickets – Diagnostics Primary biliary cholangitis – Treatment Aicardi-Goutieres syndrome – Basic Information Langerhans’ cell histiocytosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ltx-315 Filgotinib F125/10 Tinzaparin Metformin Gremubamab BMS-986470 Nipocalimab Amikacin ATTR-01 Raltegravir Brexpiprazole Fumarate Deferoxamine Bbp-398 Etidronate Disodium Hydroxi-Methionine Calcium Imipramine Hydrochloride Lorazepam Magrolimab Rifabutin More therapies…

    Learn about Your Condition

    Post procedural oedema Tendon injury Labour pain Inner ear disorder Biliary tract operation Chondropathy Rabies Prolymphocytic leukaemia Pyelonephritis acute Vaginal cancer Leiomyosarcoma Mesothelioma Left ventricular dysfunction Vulval cancer Right ventricular dysfunction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Mirikizumab
    • Tirzepatide
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Safety and Efficacy of BMS-986528 with Tocilizumab in Patients with Refractory Rheumatoid Arthritis: A Phase 1/2a Open‑Label Study

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Tocilizumab
    Germany Italy Poland Spain

  • Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast neoplasm
    Investigated Drugs:
    • Ly3484356
    • Goserelin Acetate
    • Tamoxifen Citrate
    Belgium France Germany Italy

  • Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

    Recruiting

    3 1 1
    Investigated Diseases:
    • Asthma
    Investigated Drugs:
    • Depemokimab
    Belgium Bulgaria Czechia France Germany Ireland +3

  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Carfilzomib
    • Cevostamab
    • Daratumumab
    Czechia Denmark France Germany Greece Italy +2

  • Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

    Recruiting

    4 1
    Investigated Drugs:
    • LUNSEKIMIG
    Belgium Denmark Estonia Finland France Germany +7

  • Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Croatia Czechia France Greece Hungary Italy +5

  • A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    France Germany Greece Italy The Netherlands Poland

  • Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Phase I/II Study of AZD6621 Safety and Efficacy in Adult Men with Metastatic Prostate Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Belgium Italy The Netherlands Poland Spain
1 2 3 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!